Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemetrexed versus pemetrexed + erlotinib in second-line nonsquamous NSCLC
2006-005118-11Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of pemetrexed and erlotinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Progression-free survival. Started Jan 2007; status: completed.
02
Drugs
pemetrexederlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2006-005118-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005118-11.